Episode Details

A large U.S. study found no evidence that taking Ozempic or Wegovy is tied to an increase in suicidal thoughts, researchers reported recently.

研究人员最近报告称，美国的一项大型研究发现，没有证据表明服用 Ozempic 或 Wegovy 与自杀念头增加有关。

Both Ozempic for type 2 diabetes and the obesity treatment Wegovy have the same active ingredient, semaglutide.

用于治疗 2 型糖尿病的 Ozempic 和治疗肥胖症的 Wegovy 都具有相同的活性成分：索马鲁肽。

The analysis included electronic medical record data from more than 1.8 million patients. Researchers actually found a lower risk of new and recurring suicidal thoughts in those taking semaglutide compared to those using other medications for weight loss or diabetes.

该分析包括超过 180 万名患者的电子病历数据。 研究人员实际上发现，与使用其他减肥或糖尿病药物的患者相比，服用索马鲁肽的患者出现新的和反复自杀想法的风险较低。

Semaglutide belongs to a class of drugs known as GLP-1 agonists, which were designed to treat type 2 diabetes. In addition to helping control blood sugar levels, the drugs produce a feeling of fullness.

索马鲁肽属于一类被称为 GLP-1 激动剂的药物，旨在治疗 2 型糖尿病。 除了帮助控制血糖水平外，这些药物还能产生饱腹感。

Concerns over reports of suicidal ideation connected with semaglutide led to an investigation by the European Medicines Agency. The U.S. Food and Drug Administration (FDA) has listed suicidal ideation as a possible safety concern for GLP-1 drugs.

由于对与索马鲁肽有关的自杀意念报道的担忧，欧洲药品管理局展开了调查。 美国食品和药物管理局 (FDA) 已将自杀意念列为 GLP-1 药物可能存在的安全问题。

A Reuters examination last year found that the FDA had received 265 reports of suicidal thoughts or behavior in patients taking semaglutide or similar medicines since 2010. Thirty-six of those reports describe a death by suicide or suspected suicide.